Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | Director · CHIEF EXECUTIVE OFFICER | May 16, 2024 | May 17, 2024 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | Director · President and CEO | January 31, 2019 | February 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date May 16, 2024 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-05-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-05-16 · Exercise / conversion · Acquired 10,000 · Balance 10,000 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Row 2 · 2024-05-16 · Sale · Disposed 8,707 · Balance 1,293 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $21.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 3 · 2024-05-16 · Sale · Disposed 1,293 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.87 to $22.035, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01 | Direct | 343,381 |
Reported balance
After 2024-05-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-16 · Exercise / conversion · Disposed 10,000 · Balance 343,381 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $21.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.87 to $22.035, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Protara Therapeutics, Inc.
Report date January 31, 2019 · Filed February 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2029-01-30 | Direct | 350,000 |
Reported balance
After 2019-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-31 · Grant · Acquired 350,000 · Balance 350,000 F1: The options were granted on January 31, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on January 31, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2024 Filed May 17, 2024 23:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-013629 · form4-05172024_070501.xml · derivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 343,381 Underlying: Common Stock · 10,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 16, 2024 Filed May 17, 2024 23:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,293 | $21.92 | $28,345.15 |
DisclosureSEC source: 0001415889-24-013629 · form4-05172024_070501.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.87 to $22.035, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 16, 2024 Filed May 17, 2024 23:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 8,707 | $21.52 | $187,410.34 |
DisclosureSEC source: 0001415889-24-013629 · form4-05172024_070501.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,293 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.87 to $21.84, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 16, 2024 Filed May 17, 2024 23:10 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,000 | $2.14 | $21,400.00 |
DisclosureSEC source: 0001415889-24-013629 · form4-05172024_070501.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-012234 · form4-05032024_060501.xml · derivative · entry 5 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 353,381 Underlying: Common Stock · 10,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F5 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,357 | $19.91 | $27,017.87 |
DisclosureSEC source: 0001415889-24-012234 · form4-05032024_060501.xml · nonDerivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4 · shares: Includes 1,357 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 965 | $20.87 | $20,135.01 |
DisclosureSEC source: 0001415889-24-012234 · form4-05032024_060501.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.855 to $20.89, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 9,035 | $20.34 | $183,792.68 |
DisclosureSEC source: 0001415889-24-012234 · form4-05032024_060501.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 965 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.855 to $20.85, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,000 | $2.14 | $21,400.00 |
DisclosureSEC source: 0001415889-24-012234 · form4-05032024_060501.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-011144 · form4-04182024_060401.xml · derivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 363,381 Underlying: Common Stock · 10,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,509 | $24.94 | $137,409.89 |
DisclosureSEC source: 0001415889-24-011144 · form4-04182024_060401.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.81 to $25.10, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,491 | $24.40 | $109,560.64 |
DisclosureSEC source: 0001415889-24-011144 · form4-04182024_060401.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,509 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.80 to $24.785, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 16, 2024 Filed Apr 18, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,000 | $2.14 | $21,400.00 |
DisclosureSEC source: 0001415889-24-011144 · form4-04182024_060401.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-010138 · form4-04032024_060408.xml · derivative · entry 6 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 373,381 Underlying: Common Stock · 10,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F5 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,000 | $31.95 | $31,950.00 |
DisclosureSEC source: 0001415889-24-010138 · form4-04032024_060408.xml · nonDerivative · entry 5 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,851 | $31.02 | $88,446.00 |
DisclosureSEC source: 0001415889-24-010138 · form4-04032024_060408.xml · nonDerivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.73 to $31.46, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,647 | $29.90 | $49,237.89 |
DisclosureSEC source: 0001415889-24-010138 · form4-04032024_060408.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,851 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.705 to $30.45, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,502 | $28.96 | $130,399.08 |
DisclosureSEC source: 0001415889-24-010138 · form4-04032024_060408.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,498 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.57 to $29.48, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,000 | $2.14 | $21,400.00 |
DisclosureSEC source: 0001415889-24-010138 · form4-04032024_060408.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0001415889-24-002089 · form4-01312024_060101.xml · derivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-01-28 F1 · derivative.exercise_date: The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 29, 2024. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,092 | $10.42 | $11,378.64 |
DisclosureSEC source: 0001415889-23-014773 · form4-11032023_051101.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022. F2 · shares: Includes 1,092 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,478 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-011677 · form4-08012023_060801.xml · derivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 383,381 Underlying: Common Stock · 5,478 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F2 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,478 | $18.00 | $98,604.00 |
DisclosureSEC source: 0001415889-23-011677 · form4-08012023_060801.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| July 28, 2023 Filed Aug 1, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 5,478 | $2.14 | $11,722.92 |
DisclosureSEC source: 0001415889-23-011677 · form4-08012023_060801.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,522 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-011348 · form4-07192023_060719.xml · derivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 388,859 Underlying: Common Stock · 4,522 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2023. F3 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,522 | $18.11 | $81,896.13 |
DisclosureSEC source: 0001415889-23-011348 · form4-07192023_060719.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.525, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,522 | $2.14 | $9,677.08 |
DisclosureSEC source: 0001415889-23-011348 · form4-07192023_060719.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-010832 · form4-07052023_060701.xml · derivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 393,381 Underlying: Common Stock · 10,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F2 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,000 | $18.00 | $180,000.00 |
DisclosureSEC source: 0001415889-23-010832 · form4-07052023_060701.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,000 | $2.14 | $21,400.00 |
DisclosureSEC source: 0001415889-23-010832 · form4-07052023_060701.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 693 | $21.15 | $14,656.95 |
DisclosureSEC source: 0001415889-23-007247 · form4-05032023_060501.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022. F2 · shares: Includes 693 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-007247 · form4-05032023_060501.xml · derivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,381 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022. F4 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 15,000 | $20.61 | $309,088.50 |
DisclosureSEC source: 0001415889-23-007247 · form4-05032023_060501.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 693 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.05 to $21.01, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F2 · balance_after: Includes 693 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,000 | $2.14 | $32,100.00 |
DisclosureSEC source: 0001415889-23-007247 · form4-05032023_060501.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2022. F2 · balance_after: Includes 693 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d). Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-006321 · form4-04052023_060401.xml · derivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,381 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F4 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,828 | $19.77 | $115,226.55 |
DisclosureSEC source: 0001415889-23-006321 · form4-04052023_060401.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.51 to $20.22, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 9,172 | $19.16 | $175,689.66 |
DisclosureSEC source: 0001415889-23-006321 · form4-04052023_060401.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,828 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.50 to $19.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,000 | $2.14 | $32,100.00 |
DisclosureSEC source: 0001415889-23-006321 · form4-04052023_060401.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Option (Right to Buy) · Derivative | 139,067 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0001415889-23-004514 · form4-03082023_060310.xml · derivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,067 Underlying: Common Stock · 139,067 shares Expires 2033-03-06 F1 · derivative.exercise_date: The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on April 7, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-004192 · form4-03032023_060301.xml · derivative · entry 6 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,381 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F5 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 1,050 | $25.67 | $26,953.50 |
DisclosureSEC source: 0001415889-23-004192 · form4-03032023_060301.xml · nonDerivative · entry 5 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,316 | $24.69 | $131,240.34 |
DisclosureSEC source: 0001415889-23-004192 · form4-03032023_060301.xml · nonDerivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.33 to $25.06, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 2,672 | $23.81 | $63,622.72 |
DisclosureSEC source: 0001415889-23-004192 · form4-03032023_060301.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,366 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.31 to $24.20, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 5,962 | $22.71 | $135,379.73 |
DisclosureSEC source: 0001415889-23-004192 · form4-03032023_060301.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,038 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.25 to $23.24, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,000 | $2.14 | $32,100.00 |
DisclosureSEC source: 0001415889-23-004192 · form4-03032023_060301.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-001966 · form4-02032023_060202.xml · derivative · entry 4 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,381 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F4 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,495 | $23.05 | $103,610.65 |
DisclosureSEC source: 0001415889-23-001966 · form4-02032023_060202.xml · nonDerivative · entry 3 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.815 to $23.435, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,505 | $22.52 | $236,586.26 |
DisclosureSEC source: 0001415889-23-001966 · form4-02032023_060202.xml · nonDerivative · entry 2 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,495 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.80 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 23:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 15,000 | $2.14 | $32,100.00 |
DisclosureSEC source: 0001415889-23-001966 · form4-02032023_060202.xml · nonDerivative · entry 1 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-000551 · form4-01052023_050101.xml · derivative · entry 6 NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,381 Underlying: Common Stock · 15,000 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2022. F5 · derivative.exercise_date: A total of 493,381 shares subject to an employee stock option were granted on April 2, 2021, with 25% vested on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.